CHOSA Oncology AB resolves on a directed issue of units of initially approximately SEK 7.3 million

CHOSA Oncology has resolved a directed issue of 8,967,786 units at SEK 0.82 per unit (one share + one free warrant TO3), raising approximately SEK 7.3m before estimated SEK 0.7m in issue costs, with TO3 exercisable 3–17 Nov 2026 at SEK 1.025 to potentially deliver an additional ~SEK 9.2m. The transaction increases shares from 78,895,886 to 87,863,672 (initial dilution ~10.2%); full warrant exercise would raise total shares to 96,831,458 with combined dilution ~18.5%, and management says proceeds fund commercialization, clinical studies and regulatory work to secure runway to Q3 2027. The issue was directed to existing and new investors after board assessment that a rights issue was less attractive, and Navia acted as sole manager.

Analysis

Market structure: CHOSA (CHOSA, Spotlight) gains short-term liquidity (SEK 7.3m now, plus up to SEK 9.2m if TO3 exercised Nov 2026) enabling commercialization push through Q3 2027; initial dilution ~10.2% rising to ~18.5% if warrants exercised (exercise price SEK 1.025). Winners include CHOSA, distribution partners and NanoString (NSTG) integration partners; losers are existing minority shareholders facing near-term dilution and small competing CDx providers that lack validated platinum-response data. Improved patient stratification can raise pricing power for a validated companion diagnostic and compress failed trial rates for PD(L)-1/platinum combos, improving pharma R&D ROI.

Risk assessment: Tail risks: FDA/EMA rejectiveness to claimed predictive utility or payors deny reimbursement (low-probability/high-impact); partner failures or low TO3 exercise rate causing cash shortfall are medium probability. Time horizons: immediate (days-weeks) = share reaction to directed issue and new investors; short-term (3–9 months) = conference data, partnership announcements, regulatory filing starts; long-term (12–36 months) = reimbursement, clinical adoption, revenue scaling. Hidden dependencies: reliance on NanoString workflow uptake, hospital procurement cycles, and drug developers’ willingness to adopt CDx in trial design.

Trade implications: Direct play: selective small position in CHOSA as event-driven speculative long (size 1–2% portfolio) with strict stop-loss; paired trades favor long diagnostics/precision oncology (NSTG, GH) and underweight undifferentiated R&D-stage oncology biotechs on Spotlight. Options: use protective put (or put spread) on CHOSA position to cap downside to ~30% through Nov 2026; consider long-dated calls on NSTG (9–18 months) to capture partnership-driven re-rating.

Contrarian angles: Consensus may underweight the value of NanoString compatibility — if clinical utility holds, CHOSA's addressable market could expand >2x versus base case; conversely market may be under-pricing warrant non-exercise risk (if <50% TO3 exercised, runway shortfall likely). Historical parallel: small CDx firms often re-rate only after regulatory/reimbursement wins; absence of those milestones could leave CHOSA trading below current subscription price for >12 months, creating mean-reversion opportunity.

Key Decisions for Investors

• Establish a tactical 1–2% portfolio long in CHOSA (CHOSA, Spotlight) on any >10% intraday pullback from today’s level; set stop-loss at -30% and take-profit at +50% or on confirmed partnership/FDA acceptance (whichever first).
• Buy a Mar-Nov 2026 put spread on CHOSA (if liquid) to limit downside to ~30% cost-efficiently through the TO3 exercise window; alternatively allocate 0.25–0.5% portfolio to protective puts around key conference readouts (next 3–9 months).
• Allocate 1–2% long to NanoString (NSTG) or Guardant Health (GH) via LEAP calls (12–18 months) to play platform/partner upside; target 20–40% position if CHOSA announces formal NanoString-based distribution partnerships within 6 months.
• Short or underweight a Nordic small-cap biotech basket (or Spotlight small-cap biotech ETF) by 1–3% vs. the long CHOSA exposure to hedge sector financing/dilution risk; rebalance after Nov 2026 TO3 exercise outcome (cut hedge if >70% TO3 exercised and new cash confirmed).
• Monitor three triggers over next 9 months and act: (1) regulatory filings initiated with FDA/EMA (positive -> add 0.5–1% long), (2) partnership with major genetic diagnostics player executed (positive -> double exposure to 2–4%), (3) <40% TO3 subscription indications by Sep 2026 (negative -> reduce exposure to 0.25% or exit).